All News

PSS.scleroderma.arthritis.contractures

Rituximab Efficacy in Systemic Sclerosis

d Jack Cush, MD

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Read Article
Malar,rash,SLE, Lupus

Low Dose IL-2 Therapy in SLE

d Jack Cush, MD

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).

Read Article
SCLE,DIL,PPI

Drug-Induced Lupus from Proton Pump Inhibitors

d Jack Cush, MD

A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.

Read Article
woman-1284353_640.jpg

Favorable Pregnancy Outcomes in Spondyloarthritis

d Jack Cush, MD

Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.

Read Article
JIA_0.jpg

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

d Jack Cush, MD

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.

Read Article
MSK US in Gout? 71 gout pts on ULT followed x 1yr, 42% had at least one flare (median=2). Baseline US showing MSU deposits & inflammation significantly assoc w/ with # Flares (MSU score RR 1.17; power Doppler score RR 1.29) https://t.co/6IQo4JWtK0 https://t.co/Slm0fOvbnt

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout T2T: Rheumatology societies target urate <5 mg/dl (0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l) - below point of urate saturation -->MSU crystal dissolution. Achieving target reduces flares & tophi; but these clinical benefits take time. https://t.co/qfFSpGCJZp https://t.co/ILMAX3jj50

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%, hip, ankle). OA from Injury, age, obesity. Prior knee/hip injury increased OA rates significantly (aOR 1.51/4.03) https://t.co/yZAHA8MYly https://t.co/W1StoLYjkl

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/leVXN4WNXx https://t.co/5S5nD8ZgcQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 209 Early RA (<1yr) pts found 23 (11%) with Drug Free Remission (DFR) after 74 mos of F/U; DFR maintained x 48 mo (18–82). DFR was assoc w/ early persistence on Therapy (HR 3.84). Adhering to prescribed treatment may lead to DFR https://t.co/oO8wKOKfxE https://t.co/DPX9JudplX

Links:

Dr. John Cush RheumNow ( View Tweet)
Popeye sign (=biceps tendon rupture) #MedTwitter https://t.co/vES4juLCUp
Avraham Z. Cooper, MD AvrahamCooperMD ( View Tweet)
Exciting news to announce! Our book "Telerheumatology: Origins, Current Practice, and Future Directions" is now available for download and has been published on SpringerLink. #telerheumatology #rheumtwitter #rheum https://t.co/rW0g6WByTp

Links:

Christine Peoples CPeoplesMD ( View Tweet)

Mass Gen Brigham study of Rheum (SARD) pts COVID severity over time (3/20-1/22) shows less severe COVID over time. 1449 SARD pts had COVID-19 (1/3 RA); 28% severe. Early COVID was more severe (46%) vs 15% w/ Omicron. Unvax were more severe (78% v 60%) https://t.co/DTge2od82Q https://t.co/LXeujT6zd5

Links:

Dr. John Cush RheumNow ( View Tweet)
Has insurance moved to a new tactic to intimidate doctors from appeals? I was expecting to do a peer to peer to get #Xeljanz approved, they put me on the phone with a courtroom judge to make me swear I am telling the truth about why the medicine is needed for the patient.

TheDaoIndex KDAO2011 ( View Tweet)

Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data, no RCTs. Ref product to biosimilar usually RCTs; Biosimilar switches usually real world evidence w/ good efficacy & no new risks. https://t.co/odAYHdbVd1 https://t.co/BabkVYsMBL

Links:

Dr. John Cush RheumNow ( View Tweet)
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!

Dr. John Cush RheumNow ( View Tweet)

Recurrence of axSpA in 1st-degree relatives (FDR) probands w/ 35-yrs F/U. From 363 AS probands & 806 FDR, 27.1% of B27(+) FDR developed axSpA; 18.2% from AS probands; 4% from nr-axSpA probands. Recurrence higher with B27+ probands https://t.co/1xczXdtrH3 https://t.co/mXZ72nVAqp

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Women’s Cohort -diet & Hip Fx risk study shows that amongst 26,318 women, 822 hip Fxs - Hip Fx risk was higher in Vegetarians (HR 1.33; 1.03, 1.71)) but not meat-eaters (HR 1.00; 0.85, 1.18) or pescatarians (0.97; 0.75, 1.26); unaffected by BMI https://t.co/tipy0IBp4D https://t.co/sG0lJAUgDj

Links:

Dr. John Cush RheumNow ( View Tweet)
Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/d3CPsKiR88 https://t.co/QgCYBikhyl

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×